{"entity":{"id":"nct03714334","kind":"trial","name":"DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma","aka":[],"tldr":"A phase 1 trial of DNX-2440 run by Clinica Universidad de Navarra, Universidad de Navarra, terminated.","summary":"DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma is a phase 1 interventional study registered as NCT03714334 by Clinica Universidad de Navarra, Universidad de Navarra, with 16 participants enrolled, started 2018-10-16. Conditions recorded: Glioblastoma and Glioblastoma, Adult. Interventions recorded: DNX-2440 injection.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT03714334","url":"https://clinicaltrials.gov/study/NCT03714334"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["dnx-2440"],"companies":["dnatrix"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03714334","phase":"1","setting":"Phase I Trial of DNX-2440 Oncolytic Adenovirus in Patients With Recurrent Glioblastoma","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","enrolled":16,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03714334/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"dnx-2440","kind":"drug","name":"DNX-2440","route":"/drugs/dnx-2440/"}],"company":[{"id":"dnatrix","kind":"company","name":"DNAtrix","route":"/companies/dnatrix/"}]}}